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Corneodesmosin (CDSN), desmoglein 1 (DSG1), and desmocollin 1 (DSC1) are adhesive proteins of the
extracellular part of the corneodesmosomes, the junctional structures that mediate corneocyte cohesion. The
degradation of these proteins at the epidermis surface is necessary for desquamation. Two serine proteases of the
kallikrein family synthesized as inactive precursors have been implicated in this process: the stratum corneum
chymotryptic enzyme (SCCE/KLK7/hK7) and the stratum corneum tryptic enzyme (SCTE/KLK5/hK5). Here, we
analyzed the capacity of these enzymes to cleave DSG1, DSC1, and epidermal or recombinant forms of CDSN, at an
acidic pH close to that of the stratum corneum. SCCE directly cleaved CDSN and DSC1 but was unable to degrade
DSG1. But incubation with SCTE induced degradation of the three corneodesmosomal components. Using the
recombinant form of CDSN, either with its N-glycan chain or enzymatically deglycosylated, we also demonstrated
that oligosaccharide residues do not protect CDSN against proteolysis by SCCE. Moreover, our results suggest
that SCTE is able to activate the proform of SCCE. These results strongly suggest that the two kalikreins are
involved in desquamation. A model is proposed for desquamation that could be regulated by a precisely controlled
protease–protease inhibitor balance.
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Within the stratum corneum, strong inter-corneocyte cohe-
sion is provided by corneodesmosomes, cellular junctions
derived from desmosomes (Skerrow et al, 1989; Chapman
et al, 1991) and named corneodesmosomes (Serre et al,
1991). Ultrastructural studies demonstrated that the degra-
dation of corneodesmosomes is concomitant to desqua-
mation (Chapman and Walsh, 1990; Fartasch et al, 1993).
Moreover, proteolytic cleavage of the extracellular part of
these cell–cell adhesive structures was shown to be a key
event in this process, in plantar (Lundstrom and Egelrud,
1988) as well as non-palmoplantar stratum corneum
(Egelrud and Lundstrom, 1990; Suzuki et al, 1994). Three
proteins have been described as components of the
extracellular part of corneodesmosomes: the two desmo-
somal cadherins, desmoglein 1 (DSG1) and desmocollin 1
(DSC1) that associate in a calcium-dependent manner
(Kowalczyk et al, 1999), and corneodesmosin (CDSN), a
glycoprotein secreted by granular keratinocytes and then
incorporated into the desmosomes (Serre et al, 1991).
Synthesized as a 52–56 kDa protein, CDSN is progressively
proteolysed in the stratum corneum, to yield a fragment,
probably devoid of any adhesive properties, detected only
at the skin surface (Lundstrom et al, 1994; Simon et al,
2001a). Previous data evidenced a role for CDSN in
corneocyte cohesion and strongly suggested that its
degradation is necessary for desquamation (Lundstrom
et al, 1994; Haftek et al, 1997; Simon et al, 2001b; Jonca
et al, 2002). Fragments of DSC1 were observed to
accumulate in the stratum corneum of normal epidermis
(King et al, 1987) and DSC1 proteolysis is reduced in the
stratum corneum of dry skin.1 The cleavage of DSG1 is also
concomitant with scale shedding, and its persistence is a
characteristic of hyperkeratosis (Lundstrom and Egelrud,
1990; Suzuki et al, 1996).
Molecules responsible for the cleavage of corneodes-
mosomal proteins and their mode of regulation are not well
understood. A number of different proteases of the serine,
cysteine, or aspartic protease families have been identified
in the stratum corneum and might play a role in desquama-
tion (Suzuki et al, 1993; Horikoshi et al, 1999; Watkinson,
1999; Bernard et al, 2003, for a review see Rawlings, 2003).
Abbreviations: CDSN, corneodesmosin; DSC, desmocollin; DSG,
desmoglein; MoAb, monoclonal antibody; PAGE, polyacrylamide
gel electrophoresis; SCCE, stratum corneum chymotryptic en-
zyme; SCTE, stratum corneum tryptic enzyme
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Their direct involvement in degradation of the corneodes-
mosome components, however, has not been demon-
strated. Among these proteases, the stratum corneum
chymotryptic enzyme (SCCE) and the stratum corneum
tryptic enzyme (SCTE) (Hansson et al, 1994; Suzuki et al,
1994; Brattsand and Egelrud, 1999; Ekholm et al, 2000) are
serine proteases of the kallikrein family named KLK7/hK7
and KLK5/hK5, respectively (Diamandis et al, 2000). They
are both highly expressed in granular keratinocytes and
present in the intercellular spaces of the stratum corneum
(Sondell et al, 1995; Ekholm et al, 2000). Synthesized as
inactive proforms, they are both activated by cleavage of a
short amino-terminal domain performed by an enzyme with
the characteristics of a trypsin-like protease (Hansson et al,
1994; Brattsand and Egelrud, 1999). Moreover, glycosi-
dases may also be involved in corneodesmosome degra-
dation at the skin surface since pre-treatment of stratum
corneum biopsies with endoglycosydases allowed more
complete cell dissociation following the action of exogen-
ous proteases (Walsh and Chapman, 1991). The importance
of pH for stratum corneum cohesion and desquamation was
also recently evidenced using superbases topically applied
on hairless mouse skin (Hachem et al, 2003).
For a better understanding of the desquamation me-
chanisms and to test the direct implication of SCCE and
SCTE in corneodesmosome degradation, we analyzed in
vitro, the capacity of the two enzymes to cleave the
corneodesmosome extracellular proteins. In particular, we
asked whether the serine proteases, which both have an in
vitro neutral pH optimum when tested with synthetic
substrates, conserve sufficient activity at pH 5.6, close to
the physiological pH of the stratum corneum (Ohman and
Vahlquist, 1994), to be involved in normal desquamation.
We next investigated the influence of the CDSN carbohy-
drates on its cleavage by SCCE. We report that the
combined action of SCCE and SCTE allowed degradation
at pH 5.6 of CDSN, DSG1, and DSC1, and that sugars did
not protect CDSN against proteolysis by SCCE. A model of
proteolytic events necessary for desquamation is proposed
involving a tight balance between proteases and protease
inhibitors, in a particular microenvironment.
Results
SCTE- and SCCE-induced proteolysis of corneodesmo-
somal components at pH 5.6 Since SCCE and SCTE have
both been implicated in desquamation, we analyzed
whether proteins of the extracellular part of corneodesmo-
somes are substrates for these proteases in vitro. Although
the proteolysis of CDSN has been demonstrated during
incubation with SCCE and SCTE at pH 7.2 (Simon et al,
2001a), so far no studies had been carried out to cleave
corneodesmosome components at acidic pH, the physio-
logical pH of the horny layer. Epidermal proteins were
therefore treated for 2 h with these enzymes at pH 7.2 or
5.6, and the incubated extracts were analyzed by immuno-
blotting with anti-CDSN (G36-19 and F28-27 monoclonal
antibodies (MoAb)), anti-DSG (DG3.10 MoAb), and anti-
DSC antibodies (a MoAb specifically recognizing DSC1, and
a serum directed against all three DSC isoforms).
Protogold staining of total proteins and immunoblotting
analysis with a serum directed against involucrin, another
epidermal protein, indicated that the incubation with SCTE
in an acidic environment did not induce degradation of the
major proteins of the extract, and that involucrin is not a
substrate of the enzyme (Fig 1). CDSN, however, was
degraded during the incubation. Among the produced
fragments, some were only detected by F28-27 (around
48 and 33 kDa) and others were detected by both anti-
CDSN MoAb (around 36 kDa). The degradation of DSC1
was time dependent but the protein was still detected after
2 h of incubation. Surprisingly, as opposed to the results
obtained at pH 7.2 (Simon et al, 2001a), acidic pH allowed
degradation of DSG during incubation with SCTE. No
degradation was observed for the proteins tested when
incubations were done in the absence of the enzyme (only
shown for CDSN).
Recombinant SCCE also induced complete degradation
of CDSN at pH 5.6, generating fragments of 48 and 31 kDa
(Fig 2). The CDSN fragment of 48 kDa was stained by both
MoAb G36-19 and F28-27, whereas the 31 kDa one was
only recognized by G36-19. Control experiments in the
absence of the active SCCE showed that CDSN remained
intact throughout the incubation. SCCE treatment at pH 5.6
also induced the proteolysis of DSC1, but not of DSG and
involucrin.
To evaluate the importance of pH on the degradation of
the corneodesmosome extracellular components, the im-
munoreactive bands were quantified by scanning, and rates
of proteolysis at pH 5.6 and 7.2 were compared (Fig 3).The
results clearly indicated that both SCCE and SCTE induced
degradations of CDSN and DSC1 with similar efficiency at
the acidic and neutral pH.
Production of glycosylated recombinant CDSN The
results described above strongly suggested that CDSN,
DSC1 and DSG1 are substrates of SCCE and/or SCTE. An
indirect effect of one of the enzymes mediated by activation
of another protease already present in the epidermal
extract, however, cannot be excluded. To test the direct
action of either SCCE or SCTE without the presence of
other epidermal proteases, the use of recombinant proteins
becomes a necessary tool. We produced a recombinant
form of CDSN using the EBNA-293 human cell line
transfected with CDSN cDNA (Fig 4A). To compare the
carbohydrate moiety of the recombinant and epidermal
CDSN forms, treatments with O- and N-glycosidase
(glycopeptidases specific for serine/threonine- or aspara-
gine-linked sugars, respectively) were performed. Incuba-
tion with O-glycanase did not induce any modifications in
the apparent molecular mass of either form (data not
shown). The epidermal, as well as the recombinant CDSN,
was shown to contain mainly N-linked oligosaccharides.
Indeed, treatment with N-glycosidase F induced a decrease
of  4–5 kDa in the apparent molecular mass of the
recombinant CDSN (Fig 4B), as observed with the epider-
mal form. For more detailed information on the oligosac-
charide composition, the recombinant CDSN was purified
by affinity chromatography and analyzed by affinodetection
with biotinylated lectins, as previously described (Simon
et al, 1997). Wheat germ and Pisum sativum agglutinins
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(specific for b-N-acetylglucosamine groups and for a-D-
mannose and a-D-glucose, respectively), that were shown
to bind purified epidermal CDSN (Simon et al, 1997), were
also found to bind the recombinant CDSN form (not shown).
Cleavage of the recombinant CDSN by SCCE and
inﬂuence of CDSN carbohydrates on its proteolysis The
recombinant CDSN was incubated at pH 5.6 with either
the active SCCE or the inactive pro-SCCE for 2 h at 371C.
The resulting proteolytic fragments were then analyzed by
immunodetection with G36-19 (Fig 5A) and F28-27 (data not
shown). Two of the fragments generated with an apparent
molecular mass of about 48 and 31 kDa were detected by
G36-19. As observed on proteolysis of native epidermal
CDSN, the 31 kDa CDSN fragment was only recognized by
G36-19, whereas the 48 kDa fragment was also stained by
F28-27. Incubation with the recombinant inactive pro-SCCE
was without effect on the recombinant CDSN. These results
clearly demonstrated that SCCE is able to directly cleave
CDSN.
In opposition to the epidermal protein, the recombinant
CDSN was not cleaved during incubation with the active
SCTE at pH 5.6, even when the SCTE/protein ratio was
increased by a factor of 20 (data not shown). This suggests
that the SCTE-induced degradation of the epidermal CDSN
may be due to SCTE-mediated activation of another
protease already present in the extract (see Discussion).
Absence of inﬂuence of CDSN carbohydrates on its
proteolysis by SCCE Oligosaccharides can protect cor-
neodesmosomal proteins from protease degradation and
may prevent premature desquamation as suggested by
Walsh and Chapman (1991). To assess the importance of
carbohydrates in CDSN proteolysis, degradation of the
recombinant CDSN by SCCE at pH 5.6 was compared
before and after N-glycosidase treatment. Samples were
analyzed by immunoblotting with G36-19 and F28-27 and
with 4 sera directed to various domains of CDSN (A4055,
B102115, C409423, D472486). Whatever the anti-CDSN anti-
bodies used, results showed that removal of oligosacchar-
ides from CDSN did not modify its cleavage by SCCE (Fig 5
and data not shown). All the fragments generated in each
case were the same after subtracting the mass of the
carbohydrate moiety (compare Fig 5A with B and Fig 5C with
D). Incubation with the recombinant inactive pro-SCCE was
without effect on the recombinant deglycosylated CDSN, as it
was on the glycosylated CDSN either native or recombinant.
SCTE-induced cleavage of pro-SCCE Activation of SCCE
requires the proteolytic cleavage of its propeptide by a
Figure 1
SCTE-induced degradation of epidermal proteins at pH 5.6. Proteins extracted from human epidermis in pH 5.6 sodium-acetate buffer were
incubated with (þ ) or without () SCTE at pH 5.6 for increasing periods of time as indicated above the gels. After addition of Laemmli’s sample
buffer to stop the reaction, proteins were separated by SDS-PAGE and transferred onto a nitrocellulose membrane. Proteins were either stained with
Protogold or immunodetected with DG3.10, G36-19, F28-27, or anti-DSC1 MoAb or with sera directed against involucrin or DSC1-3, as indicated.
Arrows indicate the 52–56 kDa corneodesmosin (CDSN). Stars and open arrowheads show the immunodetected CDSN fragments, already present
in the non-incubated extract or produced during incubation, respectively. The estimated molecular mass of CDSN-derived peptides (kDa) is shown
on the right. The purity of the highly enriched fraction of SCTE used, separated by SDS-PAGE and stained with protogold, is shown in the lower-left
inset. The position of molecular mass standards (kDa) is indicated on the left. SCTE, stratum corneum tryptic enzyme; DSC, desmocollin; MoAb,
monoclonal antibodies; CDSN, corneodesmosin; DSG, desmoglein.
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hitherto unknown trypsin-like protease. To test whether this
could be achieved by SCTE, the TENP-40 epidermal extract
was incubated with SCTE or with proteolysis buffer alone
for 2 h, then immunodetected with the anti-pro-SCCE23–31
serum specific for the inactive enzyme, and with an anti-
SCCE serum recognizing both the inactive and active forms
(Fig 6). As expected, the 31 kDa SCCE precursor was de-
tected by both sera in the epidermal extract (lanes 1 and 3).
Figure2
SCCE-induced degradation of epidermal
proteins at pH 5.6. Proteins extracted from
human epidermis in pH 5.6 sodium-acetate
buffer were incubated with (þ ) or without ()
SCCE at pH 5.6 for increasing periods of time
as indicated above the gels. After addition of
Laemmli’s sample buffer to stop the reaction,
proteins were immunoblotted with G36-19,
F28-27, DG3.10, anti-DSC1 MoAb and with
sera directed against DSC1-3 or involucrin, as
indicated. Arrows show the 52–56 kDa CDSN.
Stars and open arrowheads show the immu-
nodetected CDSN fragments, already present
in the non-incubated extract or produced
during incubation, respectively. The estimated
molecular mass of CDSN-derived peptides
(kDa) is shown on the right. The purified fraction
of SCCE used, separated by SDS-PAGE and
stained with protogold, is shown in the lower-
right inset. The position of molecular mass
standards (kDa) is indicated on the left. SCCE,
stratum corneum chymotryptic enzyme; MoAb,
monoclonal antibodies; DSC, desmocollin;
CDSN, corneodesmosin; DSE, desmoglein.
Figure 3
Rates of SCCE- and SCTE-induced degradation of CDSN and
DSC1 at pH 5.6 or 7.2 are similar. Epidermal extracts were incubated
at 371C for 5–120 min with SCCE or SCTE either at pH 7.2 or 5.6.
Samples were separated by SDS-PAGE and analyzed by immunoblot-
ting with monoclonal antibodies anti-DSC1 and anti-CDSN (F28-27).
Immunoreactivities of both antibodies were scanned and quantified by
densitometry. Rates of DSC1 and CDSN degradation were expressed
as percentages of remaining proteins as a function of time. SCCE,
stratum corneum chymotryptic enzyme; SCTE, stratum corneum
tryptic enzyme; CDSN, corneodesmosin; DSC1, desmocollin 1.
Figure4
Production of a glycosylated recombinant CDSN. (A) EBNA-293-
CDSN cells were grown 3 d in medium without fetal calf serum.
Proteins of conditioned medium or epidermal extract (TENP-40 buffer
extract) were separated by SDS-PAGE and immunodetected with G36-
19. (B) Proteins of either the conditioned medium dialyzed against
phosphate-buffered saline or the epidermal extract were treated (þ ) or
not () with N-glycosidase (PNGase). Then, the samples were
immunoblotted with G36-19. The position of molecular mass standards
(kDa) is indicated on the left. CDSN, corneodesmosin.
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The anti-SCCE serum indicated that incubation with SCTE
led to the appearance of a 28 kDa form of SCCE (lane 4).
Since this form was not immunodetected by the anti-pro-
SCCE2131 (lane 2), it very likely represents the active form
of the enzyme.
Discussion
In vitro and in vivo studies have demonstrated that the
cleavage of DSG1 is concomitant with scale shedding and
that its persistence at the surface of the stratum corneum is
a characteristic of hyperkeratosis (Lundstrom and Egelrud,
1990; Suzuki et al, 1996). Moreover, another protein of the
corneodesmosomes, CDSN, is progressively processed by
proteolysis from the stratum granulosum up to the stratum
corneum surface (Simon et al, 2001a). In the last step, most
of the protein is degraded and the fragment remaining is a
part of its central domain, probably devoid of adhesive
properties. Reduced proteolysis of CDSN is also observed
in xerosis and hyperkeratotic diseases (Haftek et al, 1997;
Simon et al, 2001b). This study strongly suggests that the
proteases SCCE and SCTE are the proteases involved in
Figure 5
CDSN proteolysis by SCCE is not influenced by the carbohydrate moiety of the protein. (A, C) Conditioned medium of EBNA-293-CDSN cells
was dialyzed against phosphate-buffered saline and incubated at pH 5.6 with the active SCCE or with its inactive precursor pro-SCCE for increasing
periods of time. After addition of Laemmli’s sample buffer to stop the reaction, proteins were immunoblotted with G36-19 or with the serum C409423.
(B, D) The dialyzed conditioned medium (NT) was treated with N-glycosidase (PNGase) for 3 h, then incubated with the active SCCE or with the
inactive pro-SCCE for increasing periods of time as indicated above the gels. Samples were immunoblotted with G36-19 or with the serum C409423
(B, D). Open arrowheads on the left show the immunodetected CDSN fragments. The position of molecular mass standards (kDa) is indicated on the
left. CDSN, corneodesmosin; SCCE, stratum corneum chymotryptic enzyme.
Figure6
Cleavage of pro-SCCE using SCTE. Proteins extracted from human
epidermis in pH 5.6 sodium-acetate buffer were incubated with (þ ) or
without () SCTE at pH 5.6 for 2 h. Samples were immunoblotted with
anti-pro-SCCE2331 and anti-SCCE sera. Arrows indicate the pro-
SCCE and its proteolysed form, probably corresponding to SCCE (31
and 28 kDa, respectively). The position of molecular mass standards
(kDa) is indicated on the left. SCCE, stratum corneum chymotryptic
enzyme; SCTE, stratum corneum tryptic enzyme.
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these degradation processes, supporting the hypothesis
that they are among the actors responsible for corneocyte
dissociation and desquamation. Indeed, their combined
action could degrade all the molecules essential for
corneocyte cohesion. In agreement, both trypsin-like and
chymotrypsin-like proteases have been suggested to be
involved in the proteolysis of DSG1 (Suzuki et al, 1994, 1996).
In our assays, we used 50 ng of protease for 70 mg of
epidermal proteins, which is a rather low protease/substrate
ratio, as compared to a 1:10 (w/w) ratio of hK6:extracellular
matrix protein used by others (Bernett et al, 2002). We
cannot claim, however, that the ratio is actually physiolo-
gically relevant. Particularly because, to our knowledge, the
concentration of proteases in the microenvironment close
to the corneodesmosomes is unknown.
We have shown that CDSN and DSC1 are good
substrates for both SCCE and SCTE in vitro at pH 7.2,
unlike DSG (Simon et al, 2001a; Fig 3). We showed in this
paper that degradation of the corneodesmosome proteins
by SCCE and SCTE is effective at pH 5.6, the pH of the
stratum corneum. CDSN was a good substrate for SCCE at
both pH values tested, the immunoreactive fragments
produced being distinct, whereas cleavage of DSC1 by this
protease seemed to be more prominent at the acidic pH.
CDSN and DSC1 were also proteolysed during incubation
with SCTE at the two pH values, but degradation of DSG1
occurred only at the acidic pH. These results suggest that
SCCE and SCTE have become adapted to retain activity
within the acidic stratum corneum intercellular space.
Likewise, SCCE activity is assumed to have become
tolerant to the dry conditions of the stratum corneum
(Watkinson et al, 2001). The hydratation and pH of the
stratum corneum probably constitute important elements in
regulation of its enzyme activities including proteolysis, and
therefore contribute to epidermis homeostasis (Rippke et al,
2002; Hachem et al, 2003).
In a recent study using in situ zymographic assays, P.
Elias and his team did not detect serine protease activity in
the stratum corneum of hairless mouse skin. Increasing the
stratum corneum pH, however, induced the detection of the
serine protease activity and the enhancement of cor-
neodesmosome degradation (Hachem et al, 2003). This
apparent discrepancy with our in vitro observation of a clear
activity of SCCE and SCTE at pH 5.6 could be explained by
a difference either in the sensitivity of the assays or between
species. Alternatively, it may suggest that, in vivo, the pH
controls the activation rate of serine protease proforms
rather than protease activity.
Production of a recombinant form of CDSN using
transfected 293-EBNA cells allowed us to prove the action
of SCCE on CDSN. Incubation at pH 5.6 of an epidermal
extract containing CDSN and the recombinant form of
CDSN generated the same fragments. Therefore, we
conclude that SCCE acts directly without an intermediate
step. SCTE, however, was unable to degrade the recombi-
nant CDSN in the same conditions. This could indicate that
an inhibitor of SCTE was present in the conditioned medium
containing the recombinant protein and was not eliminated
during dialysis. Alternatively, the degradation of the native
epidermal CDSN during incubation with SCTE may be due
to an indirect effect, SCTE activating another protease
already present in the TENP-40 epidermal extract in its
proform. Regarding this result, we cannot totally exclude
that degradation of the two desmosomal cadherins DSG1
and DSC1 during the incubations with SCTE is also due to a
second SCTE-activated protease.
Walsh and Chapman (1991) reported that in vitro, pre-
treatments of stratum corneum with glycosidases render
corneodesmosomes more sensitive to protease degrada-
tion probably by making corneodesmosomal proteins more
accessible to proteases. The recombinant CDSN also
allowed us to test the effect of its N-glycan chain on its
proteolysis. Like the epidermal CDSN, the recombinant
form is mainly N-glycosylated, detected by the same
lectins, and its sugar moiety also presents a molecular
mass of 4–5 kDa. To assess the importance of the glycan
chain, the susceptibility to SCCE degradation, at pH 5.6, of
the glycosylated and the enzymatically deglycosylated
recombinant CDSN were compared. We demonstrated that
the removal of the sugars does not modify SCCE cleavage
sites on CDSN and has no incidence on the proteolysis
efficacy in vitro. These results are in agreement with our
previous study, showing that the larger fragments of human
CDSN extracted from the stratum corneum are still
glycosylated (Simon et al, 2001a). Although carbohydrate
moieties do not protect CDSN against proteolysis by SCCE
in vitro, they could nevertheless protect it against degrada-
tion by other epidermal proteases. More likely, they could
modulate its adhesive properties.
Cleavage of its propeptide by an unknown trypsin-like
protease is necessary for SCCE activation. Hansson et al
(1994) demonstrated that in vitro, tryptic digestion of a
recombinant form of pro-SCCE removed the propeptide
and yielded a proteolytically active protein with the same
NH2-terminal amino acid sequence as the native SCCE.
SCTE has already been proposed to participate in this
activation but our results provide the first experimental
evidence for its actual involvement. Indeed, we observed
that the SCCE precursor, present in the epidermal extracts
used, is cleaved and probably activated by SCTE. In
agreement, we observed that native as well as recombinant
SCTE activate recombinant pro-SCCE but at low rates (T.
Egelrud and M. Brattsand, unpublished data). Such a
cascade of protease activation is well known in other
physiological processes, e.g. coagulation.
Considering our results and other published data, we
suggest that desquamation is the result of a tightly
regulated multi-step proteolytic event and we propose a
model involving proteases and protease inhibitors in the
desquamation process (Fig 7). In addition to SCCE and
SCTE, it has been proposed that other proteases take part
in desquamation according to data from zymographic
analyses and assays with specific protease inhibitors. The
enzymes are two cysteine proteases, cathepsin L2/stratum
corneum thiol protease (SCTP) stratum corneum cathepsin
L-like enzyme (Watkinson, 1996; Bernard et al, 2003), and
two aspartic proteases, cathepsin D-like and cathepsin E-
like (Horikoshi et al, 1998, 1999; Bernard et al, 2003). In
agreement, DSC1 is degraded by partially purified SCTP
(Watkinson, 1996) and CDSN was recently shown to be a
substrate of the stratum corneum cathepsin L-like enzyme
(Bernard et al, 2003). The importance of another cathepsin
1240 CAUBET ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
in desquamation was also evidenced by the recent
identification of cathepsin C missense and nonsense
mutations, resulting in undetectable activity, in Papillon–
Lefe`vre syndrome, a periodontal disease associated with
palmoplantar hyperkeratosis (Toomes et al, 1999). Synthe-
sized as proenzymes, cathepsins also undergo proteolytic
maturation but the proteases involved have not been
definitely identified. These cathepsins are present in the
stratum corneum and are active in an acidic environment
but their real role in desquamation remains to be elucidated.
Their in vitro actions on corneodesmosome proteins will be
tested in a future work.
A variety of serine protease inhibitors is also present in
the extracellular spaces of the stratum corneum and they
probably participate in the regulation of desquamation-
associated proteolysis. Among them, antileukoproteinase
(ALP) also called secretory leukocyte protease inhibitor
(SLPI) has been found, in vitro, to prevent the detachment of
corneocytes from human plantar epidermis and to strongly
inhibit SCCE activity on synthetic substrates (Franzke et al,
1996). Thus, it may be a relevant human inhibitor for SCCE
in vivo. Interestingly, ALP can be cleaved and inactivated by
members of the cathepsin family in vitro (Taggart et al,
2001). In addition to their potential role in degradation of
corneodesmosomal components, cathepsins may thus take
part in the control of SCCE activity. Elafin, formerly known
as the skin-derived-antileukoprotease (SKALP) and mem-
ber of the trappin protein family, has also been shown to be
a weak but efficient inhibitor of SCCE and to significantly
reduce the shedding of corneocytes in vitro (Franzke et al,
1996). Although principally detected during inflammation
processes, elafin was found covalently bound to the
corneocyte cornified envelopes in the normal stratum
corneum (Steinert and Marekov, 1995; Schalkwijk et al,
1999). Also expressed in the upper layers of the epidermis,
the lymphoepithelial Kazal-type 5 serine protease inhibitor
(LEKTI), encoded by the SPINK-5 gene may also target
SCCE and SCTE. Mutations of SPINK-5 cause Netherthon
syndrome, a congenital ichthyosis characterized by a
defective inhibitory regulation of desquamation leading to
a severe skin permeability barrier dysfunction (Chavanas et
al, 2000; Komatsu et al, 2002). Finally, human epidermis
contains specific cysteine protease inhibitors: cystatin a
and cystatin M/E. Interestingly, cystatin M/E expression is
restricted to the epidermis (Zeeuwen et al, 2001) and a null
mutation in its gene causes hyperkeratotic epidermis and
abnormal hair follicles in mice (Zeeuwen et al, 2002). This
strongly supports the participation of cystatins in the
physiological regulatory events of desquamation.
As a whole, our data strongly suggest that in the stratum
corneum protease activation and levels of protease in-
hibitors are in fine balance which is essential for skin
homeostasis. A better understanding of the proteolytic
cascade and of the regulatory mechanisms involved in
Figure 7
Regulation of desquamation: a model. Both SCCE/KLK7 and SCTE/KLK5, which we propose to be involved in the degradation of the extracellular
components of corneodesmosomes (CDSN, DSG1, and DSC1) and in desquamation, are produced as inactive proforms. They are activated by
tryptic cleavage of a short amino-terminal domain. Whereas the SCTE activator is unknown – it may be an autoactivation – pro-SCCE seems to be
activated by SCTE. Other proteases, mainly cathepsins, are detected in the stratum corneum and have been proposed to participate in degradation
of the corneodesmosome components. At the acidic pH of the stratum corneum, the active SCCE cleaves CDSN and DSC1. The active SCTE also
induces proteolysis of CDSN, DSC1, and DSG1, either directly or indirectly activating another protease. Some cathepsins (see details in Discussion)
have also been shown to cleave CDSN or DSC1. Proteolytic activities of SCCE and SCTE are regulated by their chemical and biochemical
microenvironment in the stratum corneum. Among these regulatory elements, elafin, secretory leukocyte protease inhibitor (SLPI), lymphoepithelial
Kazal-type 5 serine protease inhibitor (LEKTI), and cystatins, inhibitors of serine and/or cysteine proteases, are probably involved in regulating
desquamation. When the direct effect of a protease has not been demonstrated, the corresponding proteolytic activity is shown by an open arrow.
The question marks indicate unknown protease activators. SCCE, stratum corneum chymotryptic enzyme; SCTE, stratum corneum tryptic enzyme;
CDSN, corneodesmosin; DSG1, desmoglein 1; DSC1, desmocollin 1.
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desquamation should enable the design of new treatments
for skin disorders associated with disturbance in stratum
corneum turnover.
Materials and Methods
Antibodies Characteristics of the antibodies used in this study
are summarized on Table I. Affinity-purified polyclonal antibodies
A4055, B102115, C409423, and D472486 directed against various
domains of CDSN (amino acids 40–55, 102–115, 409–423, 472–486,
respectively), and the anti-CDSN MoAb G36-19 and F28-27 were
produced and characterized in our laboratory (Serre et al, 1991;
Guerrin et al, 1998; Simon et al, 2001a). DG3.10, a MoAb directed
to human DSG1 and DSG2, was purchased from Progen
Biotechnik GmbH (Heidelberg, Germany). Rabbit sera directed
against the three human DSC (anti-DSC1-3) and against involucrin
were purchased from Serotec (Oxford, UK) and from Biomedical
Technologies Inc. (Stoughton, California), respectively. A MoAb
directed to human DSC1 was from Research Diagnostic Inc.
(Flanders, New Jersey). Affinity-purified polyclonal antibodies
specific for the pro-SCCE or directed to both pro-SCCE and
active SCCE were elicited in rabbits by injection of synthetic
peptides conjugated via a C-terminal cysteine residue to keyhole
limpet hemocyanine, as reported before (Simon et al, 2001a).
According to the predicted amino acid sequence of the enzyme
(Genbank accession number L33404) the peptide EEAQGDKIIC
(amino acids 23–31) with an added C-terminal cysteine residue
was used to produce the serum anti-pro-SCCE2331, directed to
the region specific for the precursor. A mixture of three synthe-
tic peptides, with an added N-terminal cysteine residue,
CKMNEYTVHLGSDT (amino acids 71–84), CDRRAQRIKASKSF
(amino acids 87–99), and CKLISPQDCTKVYKDL (amino acids 169–
183), was used to produce the serum anti-SCCE recognizing both
inactive and active forms of SCCE. The anti-sera were affinity
purified on their corresponding peptide(s), as already described
(Simon et al, 2001a). The specificity of the affinity-purified
antibodies was evidenced using recombinant pro-SCCE and
SCCE, and a fraction of plantar stratum corneum highly enriched
in pro-SCCE and SCCE (Simon et al, 2002). None of the sera
reacted with SCTE (data not shown).
Extraction of proteins from human epidermis Dermo-epidermal
cleavage of breast skin obtained from female undergoing plastic
surgery (after informed consent and in accordance with Helsinki
principles) and without any history of skin diseases was performed
by heat treatment. The epidermis was extracted in a Tris-EDTA
buffer containing Nonidet P-40 at pH 7.2 (TENP-40 buffer extract),
as previously described (Simon et al, 1997). To obtain protein
extracts at pH 5.6, the epidermis was extracted on ice in the
following buffer: 100 mM sodium acetate pH 5.6, 0.15 M NaCl,
0.5% Nonidet P-40. The results reported in this paper were
reproducibly obtained using at least two separate extracts
prepared from two different individuals.
Recombinant CDSN
Sub-cloning experiments The p14.9 plasmid (Guerrin et al, 1998)
was digested with the restriction enzymes HindIII and NotI and the
resulting fragment containing human CDSN cDNA sequence
(GenBank accession number AF030130, CDSN allele 1.71) was
sub-cloned into the pCEP4 vector (Invitrogen Corporation,
Carlsbad, CA) giving rise to the pCEP4-CDSN plasmid.
Expression in mammalian cells The human embryonic kidney cell
line EBNA-293 (Invitrogen) was grown in Dulbecco’s modified
Eagle’s medium supplemented with 10% fetal calf serum (Bio
media, Toulouse, France) and 250 mg per mL Geneticin (G418
sulfate). Cells (2  106) were transfected using 6 mL of a non-
liposomal formulation (FuGENE 6 Transfection Reagent, Roche
Molecular Biomedicals Roche Diagnostics Corporation, Indiana-
polis, IN) and 2 mg of pCEP4-CDSN. Stable transfected cells
(EBNA-293-CDSN) were selected and maintained in the presence
of 0.2 mg per mL hygromycin. They were rinsed three times with
serum-free medium and grown in the absence of serum for 3 d.
The resulting conditioned medium was then centrifuged for 10 min
at 3000 g to eliminate cell debris and stored at 801C.
Recombinant SCCE and pro-SCCE Recombinant pro-SCCE was
produced using murine C127 cells, purified and activated with
agarose-bound trypsin as previously described (Hanson et al, 1994).
Epidermal SCTE A fraction highly enriched in native SCTE and
devoid of other protease activities as detected by zymography was
prepared as described (Brattsand and Egelrud, 1999). Briefly,
Table I. Antibodies used for immunoblotting
Antibodies Speciﬁcity Source, reference
Monoclonal antibodies
G36-19 Human CDSN (amino acids 306–309) Serre et al (1991); Guerrin et al (1998)
F28-27 Human CDSN (amino acids 349–354) Serre et al (1991); Guerrin et al (1998)
DG3.10 Human, mouse, and bovine DSG1 and DSG2 Progen Biotechnik GmbH
Anti-DSC1 Human DSC1 Research Diagnostic Inc.
Sera
Serum A40–55 Human CDSN (amino acids 40–55) Simon et al (2001)
Serum B112–115 Human CDSN (amino acids 112–115) Simon et al (2001)
Serum C409–423 Human CDSN (amino acids 409–423) Simon et al (2001)
Serum D472–486 Human CDSN (amino acids 472–486) Simon et al (2001)
Serum anti-DSC1-3 Human DSC1, DSC2, and DSC3 Serotec Ltd
Serum anti-involucrin Human involucrin Biomedical Technologies Inc.
Serum anti-pro-SCCE Human pro-SCCE (amino acids 23–31) Simon et al (2002)
Serum anti-SCCE Human SCCE (amino acids 71–84, 87–96 and 169–183) Simon et al (2002)
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plantar stratum corneum was ground in a mortar, homogenized in
Tris-HCl buffer, pH 7 and incubated for 1 h at room temperature.
The recovered pellet was extracted with 1 M acetic acid. The
extract was cleared by centrifugation and filtration and subjected
to a reversed phase chromatography. Fractions containing SCTE,
as detected by zymography and immunoblotting, were purified by
gel exclusion in 0.2 M acetic acid and 0.3 M NaCl buffer.
Protein electrophoresis and immunoblotting Proteins were
separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE)
and electro-transferred to reinforced nitrocellulose membranes.
Membranes were stained with either Ponceau Red or Protogold
(British BioCell International, Cardiff, UK) and probed with
antibodies as previously reported (Simon et al, 1997). G36-19
and F28-27 were diluted to 0.1 mg per mL, DG3-10 and anti-DSC1
to 0.5 mg per mL. Affinity-purified anti-peptide antibodies to CDSN
were diluted to 1/100, anti-pro-SCCE23–31 and anti-SCCE to 1/
1000, anti-DSC1-3 to 1/2000 and anti-involucrin to 1/200.
Immunoreactivities were revealed with the ECL Western blotting
kit as described by the manufacturer (Amersham Pharmacia
Biotech, Uppsala, Sweden).
Deglycosylation experiments Medium conditioned by EBNA-
293-CDSN cells was dialyzed against phosphate-buffered saline
using dialysis tubing WMCO 10,000 (Pierce, Tattenhall, Cheshire,
UK). Ten microgram of protein and either 2 U of N-glycosidase F
(EC 3.5.1.52; Roche Molecular Biochemicals) or an equal volume
of buffer were incubated at 371C for 3 h. The reactions were
stopped by boiling for 2 min in sample buffer. Treated and mock
samples were separated by SDS-PAGE and analyzed by immuno-
blotting.
Proteolysis experiments Treatments were performed either at pH
7.2 or 5.6 as described previously (Simon et al, 2001a) with the
following modifications. When treatments were performed with
SCTE, a solution of 0.5 M Tris was used to adjust the pH of the
protease fraction (initial pH of 2). At the neutral pH, 50 ng of
recombinant pro-SCCE or SCCE, or 100 ng of enriched epidermal
SCTE (buffered at pH 7.2) or an equivalent volume of the
proteolysis buffer (10 mM sodium phosphate buffer, pH 7.2, 0.15
M NaCl), were added to 70 mg of proteins from the TENP-40 buffer
extract. At the acidic pH, the same amount of proteases (buffered
at pH 5.6) or an equivalent volume of the acidic proteolysis buffer
(50 mM sodium acetate buffer, pH 5.6, 0.15 M NaCl), were added
to 70 mg of epidermal proteins extracted at pH 5.6. To cleave the
recombinant CDSN at acidic pH, conditioned medium of EBNA-
293-CDSN cells, was dialyzed against acidic proteolysis buffer and
70 mg of total proteins were mixed with 500 ng of SCCE or pro-
SCCE or with various amounts (100 ng–2 mg) of the fraction
enriched in epidermal SCTE. In all proteolysis experiments,
mixtures were incubated at 371C for 2 h and reactions were
stopped by boiling for 2 min in sample buffer. Samples were
separated by SDS-PAGE and analyzed by immunoblotting as
described above. The immunoblotting reactivities were scanned
and quantified by densitometry using TotalLab v2003.2 software
(Nonlinear Dynamics, Durham, North Carolina).
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